Study of BMS-986489 vs durvalumab in limited stage small cell lung cancer

An open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer (TIGOS-LS) (CA245-0004)

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

An open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer (TIGOS-LS) (CA245-0004)

For More Information:

https://clinicaltrials.gov/study/NCT06773910?term=An%20open-label,%20randomized%20study%20of%20BMS-986489%20small-cell%20lung%20cancer%20&rank=1